White carbon black: an "invisible carrier" in the pharmaceutical field

At Pfizer's oral capsule production line, a new type of sustained-release material is attracting attention: drug molecules are loaded into nanochannels of mesoporous white carbon black (pore size 2-50nm), and continuous release for 12 hours is achieved by adjusting the pore size. This technique reduces the daily medication frequency of diabetes patients from three times to one time, and reduces the fluctuation range of blood sugar by 40%.


The pharmaceutical applications of white carbon black extend far beyond this. As a vaccine adjuvant, its porous structure can adsorb antigens and enhance immune response; As a hemostatic material, gas-phase white carbon black can form a coagulation barrier within 30 seconds and is used in battlefield emergency and surgical procedures; Even in the delivery of anticancer drugs, tumor targeted release can be achieved through functional modification.


In 2025, the first white carbon black based anti-cancer drug "NanoSil Dox" approved by FDA will be launched, which will load doxorubicin on the surface of aminated white carbon black, increase the killing efficiency of breast cancer cells by five times, and reduce the cardiac toxicity. The global pharmaceutical grade white carbon black market is expanding at an annual growth rate of 18% and is expected to reach $2.5 billion by 2030.